The EVP of Zoetis (NYSE: ZTS) is Selling SharesBy Carrie Williams
This is Peck’s first Sell trade following 7 Buy transactions. In addition to Kristin Peck, one other ZTS executive reported Sell trades in the last month.
Based on Zoetis’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $1.24 billion and quarterly net profit of $239 million. In comparison, last year the company earned revenue of $1.21 billion and had a net profit of $189 million. The company has a one year high of $53.14 and a one year low of $38.26. ZTS’s market cap is $24.53B and the company has a P/E ratio of 35.96.
Based on 8 analyst ratings, the analyst consensus is Strong Buy with an average price target of $57.33, reflecting a -12.5% downside. Three different firms, including BMO Capital and Goldman Sachs, currently also have a Sell rating on the stock.
The insider sentiment on Zoetis has been negative according to 23 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
Zoetis, Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The company was founded in July 2012 and is headquartered in New York, NY.